Industry Reports

Published on: 01/09/2020
Demand in the Medical Device Outsourcing industry has been fueled by a period with remarkable innovation and adoption of new medical technologies as well as the noticeable graying of the U.S. population and corresponding increase in chronic disease and healthcare utilization.  
Published on: 01/09/2020
Robust consolidation activity among outsourced pharmaceutical providers, particularly Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs), has been driven by pharmaceutical companies seeking to reduce costs and obtain expertise and talent associated with all phases of drug development and production.  
Published on: 11/19/2019
We are witnessing an unprecedented level of merger and acquisition (M&A) activity and once-in-a-generation valuations for quality providers of autism and childhood behavioral health services.
Published on: 10/17/2019
The fundamentals in the Pharmaceutical Outsourcing industry remain solid as the sector continues to benefit from a record number of drugs under development and a rise in research and development initiatives targeting rare diseases.
Published on: 09/20/2019
The Medical Device Outsourcing industry’s strong growth prospects and favorable fundamentals and demographic trends, coupled with the glut of private equity dry powder, is spurring deal activity from financial buyers.
Published on: 09/11/2019
The deployment of digital technologies such as digital health records, telehealth, and artificial intelligence has driven the advancement of the Healthcare Information Technology industry.
Published on: 09/09/2019
The rapidly aging U.S. population not only boosts healthcare utilization but reduces the supply of healthcare professionals as aging clinicians retire and choose to work fewer hours.
Published on: 09/09/2019
The increasing volume of gene therapy drugs under development will require greater manufacturing capacity and, in turn, greater utilization of CDMO capacity.  CDMOs may be able to increase penetration of their outsourced manufacturing services by providing services at the commercial stage in addition to the earlier stages of preclinical development and clinical trials.
Published on: 07/26/2019
Capstone Headwaters’ Q2 Pharmaceutical Outsourcing Executive Summary discusses the active M&A market in the industry, fueled by pressures faced by pharmaceutical companies to accelerate drug development and displace profit drops.  To learn more about the content of the report or Capstone Headwaters’ Healthcare practice, please reach out to Eric Williams.  
Published on: 07/11/2019
Capstone Headwaters’ Q2 2019 Behavioral Healthcare Services Coverage Report discusses how the industry continues to grow, driven by the destigmatization of mental health, an influx of care options, and greater political awareness around mental health.

Pages